Initial treatment for patients with chronic myeloid leukemia
| Autor: | M Baccarani |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Oncology
medicine.medical_specialty business.industry Proceedings Article Myeloid leukemia Ocean Engineering Imatinib Philadelphia chromosome medicine.disease respiratory tract diseases Dasatinib Transplantation Nilotinib Internal medicine hemic and lymphatic diseases medicine Stem cell business Tyrosine kinase medicine.drug |
| Zdroj: | Leukemia supplements. 1(Suppl 2) |
| ISSN: | 2044-5210 |
| Popis: | The first-line treatment of chronic myeloid leukemia is based on the three currently available tyrosine kinase inhibitors (TKIs), namely imatinib, nilotinib and dasatinib. Nilotinib and dasatinib are more potent, and it is predicted that, in comparison with imatinib, they can reduce the risk of progression and increase the number of the patients who can discontinue the treatment without relapsing. Other TKIs are still being developed and may help to improve treatment options further on. Hydroxyurea has no longer a role. Allogeneic stem cell transplantation is the treatment of choice for the advanced phases, and in case of resistance to at least two TKIs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink